These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26324269)

  • 1. Greater ciprofloxacin tolerance as a possible selectable phenotype underlying the pandemic spread of the H30 subclone of Escherichia coli sequence type 131.
    Johnson JR; Porter SB; Thuras P; Johnson TJ; Price LB; Tchesnokova V; Sokurenko EV
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7132-5. PubMed ID: 26324269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity and Mechanisms of Fluoroquinolone Resistance within the H30 and H30Rx Subclones of Escherichia coli Sequence Type 131 Compared with Other Fluoroquinolone-Resistant E. coli.
    Johnson JR; Johnston B; Kuskowski MA; Sokurenko EV; Tchesnokova V
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4471-80. PubMed ID: 25987621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
    Morgan-Linnell SK; Becnel Boyd L; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):235-41. PubMed ID: 18838592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MECHANISMS OF RESISTANCE TO CIPROFLOXACIN AND GENETIC DIVERSITY OF ESCHERICHIA COLI STRAINS ORIGINATING FROM URINE CULTURES PERFORMED FOR ROMANIAN ADULTS.
    Cristea VC; Oprea M; Neacşu G; Gîlcă R; Popa MI; Usein CR
    Roum Arch Microbiol Immunol; 2015; 74(3-4):73-8. PubMed ID: 27328520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro selection of resistance to pradofloxacin and ciprofloxacin in canine uropathogenic Escherichia coli isolates.
    Liu X; Lazzaroni C; Aly SA; Thungrat K; Boothe DM
    Vet Microbiol; 2014 Dec; 174(3-4):514-522. PubMed ID: 25465666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms accounting for fluoroquinolone multidrug resistance Escherichia coli isolated from companion animals.
    Liu X; Boothe DM; Thungrat K; Aly S
    Vet Microbiol; 2012 Dec; 161(1-2):159-68. PubMed ID: 22877517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of plasmid-mediated quinolone resistance determinants among Escherichia coli isolated from food animals in Korea.
    Tamang MD; Nam HM; Chae MH; Kim SR; Gurung M; Jang GC; Jung SC; Lim SK
    Foodborne Pathog Dis; 2012 Dec; 9(12):1057-63. PubMed ID: 23186547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosomal mutations that accompany qnr in clinical isolates of Escherichia coli.
    Vinué L; Hooper DC; Jacoby GA
    Int J Antimicrob Agents; 2018 Mar; 51(3):479-483. PubMed ID: 29360506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates.
    Bansal S; Tandon V
    Int J Antimicrob Agents; 2011 Mar; 37(3):253-5. PubMed ID: 21236644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of fluoroquinolone resistance in Escherichia coli isolates from food-producing animals.
    Karczmarczyk M; Martins M; Quinn T; Leonard N; Fanning S
    Appl Environ Microbiol; 2011 Oct; 77(20):7113-20. PubMed ID: 21856834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations That Enhance the Ciprofloxacin Resistance of Escherichia coli with qnrA1.
    Vinué L; Corcoran MA; Hooper DC; Jacoby GA
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1537-45. PubMed ID: 26711751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The first report of the qnrB19, qnrS1 and aac(6´)-Ib-cr genes in urinary isolates of ciprofloxacin-resistant Escherichia coli in Brazil.
    Paiva MC; Nascimento AM; Camargo IL; Lima-Bittencourt CI; Nardi RM
    Mem Inst Oswaldo Cruz; 2012 Aug; 107(5):687-9. PubMed ID: 22850962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geographic distribution of fluoroquinolone-resistant Escherichia coli strains in Asia.
    Uchida Y; Mochimaru T; Morokuma Y; Kiyosuke M; Fujise M; Eto F; Harada Y; Kadowaki M; Shimono N; Kang D
    Int J Antimicrob Agents; 2010 Apr; 35(4):387-91. PubMed ID: 20138480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
    Chen JY; Siu LK; Chen YH; Lu PL; Ho M; Peng CF
    Microb Drug Resist; 2001; 7(1):47-53. PubMed ID: 11310803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
    Zhao X; Quinn B; Kerns R; Drlica K
    J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens.
    Chenia HY; Pillay B; Pillay D
    J Antimicrob Chemother; 2006 Dec; 58(6):1274-8. PubMed ID: 17040923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.
    Guillard T; Cambau E; Chau F; Massias L; de Champs C; Fantin B
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5830-5. PubMed ID: 24018262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.